Author(s)

Jan M. Kitzen^1,2, Joseph V. Pergolizzi Jr.³, Robert Taylor Jr.³, Robert B. Raffa^4,5

¹Kitzen Pharmaceutical Consulting, Collegeville, USA.
²Temple University School of Medicine, Philadelphia, USA.
³NEMA Research, Inc., Naples, USA.
⁴University of Arizona College of Pharmacy, Tucson, USA.
⁵Temple University School of Pharmacy, Philadelphia,USA.

When any type of product has been ordered to be removed from the marketplace by a governmental regulatory body, that action is a powerful indicator that the product has been determined to be unsafe for further use, thereby branding the product as defective and opening up the possibility of product liability litigation. When the product is a drug or medical device, it is especially serious since the possibility of personal injury (acute and/or chronic) or death may occur. Needless to say, in these situations, product injury litigation will almost surely follow. We review the definition and requisite claims needed to establish drug product liability, and the role that the medical literature, clinical trial data, and even experimental research data can play in product (drug)-injury litigation. We show how each of these resources played a significant role in two well-known cases: Fen-Phen and thimerosal. The ultimate goal of such knowledge is to make better informed decisions about drug safety.

Drug Safety, Product Quality, Injury, Litigation, Fen-Phen, Thimerosal

Kitzen, J. , Pergolizzi Jr., J. , Taylor Jr., R. and Raffa, R. (2018) The Role of Medical Literature, Clinical Trials and Experimental Research in Drug Product-Injury Litigation: A Primer with Two Examples. Pharmacology & Pharmacy, 9, 208-227. doi: 10.4236/pp.2018.96016.